DeFloria Receives Investigational New Drug Application Clearance from FDA for Phase 2 Clinical Trial of AJA001, an Oral Cannabinoid Drug Being Developed for the Treatment of Autism Spectrum Disorder (ASD)

DeFloria plans to initiate a Phase 2 clinical trial by mid-year 2025 LITTLETON, Colo., Feb. 24, 2025 /PRNewswire/ — DeFloria, Inc., a collaboration between Ajna BioSciences PBC and Charlotte’s Web Holdings, Inc. (TSX: CWEB, OTCQX: CWBHF), announced that the U.S. Food and Drug…